Алендронат в лечении остеопороза

1. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997; 103 (2A): 3–11.
2. Davidson MR. Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health 2003; 48: 39–52.
3. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underdiagnosed and undertreated. Med J 2004; 180 (5): 18–22.
4. Heaney RP. Advances in therapy for osteoporosis. Clin Med Res 2003; 1 (2): 93–9.
5. Михайлов Е.Е., Беневоленская Л.И. Эпидемиология остеопороза и переломов. Руководство по остеопорозу (под ред. проф. Л.И.Беневоленской). М.: БИНОМ, 2003; 
с. 10–53.
6. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4 (1): 30–4.
7. Hochberg MC, Greenspan S, Wasnich RD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586–92.
8. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9 (5): 461–8.
9. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85 (11): 4118–24.
10. Black DM, Schwartz AV, Ensrud K.E et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296 (24): 2927–38. 
11. Wells GA, Cranney A, Peterson J et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; 23 (1): CD001155.
12. Schnitzer T, Bone HG, Grepaldi G et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000; 12: 1–12.
13. Rizzoli R, Greenspan SL, Bone G 3rd et al. Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. J Bone Mineral Research 2002; 17 (11): 1988–96.
14. Simon JA, Lewiecki EM, Smith ME et al. Patient preference for once-weekly alendronate 70 mg versus once–daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002; 24 (11): 1871–86.
15. Greenspan S, Field-Munves E, Tonino R et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77 (10): 1044–52.
16. Lanza F, Sahba B, Schwartz H et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002; 97 (1): 58–64.
17. Breijawi N, Eckardt A, Pitton MB et al. Bone mineral density and vitamin D status in female and male patients with osteoarthritis of the knee or hip. Eur Surg Res 2009; 42 (1): 1–10.
18. Bischoff HA, Stahelin HB, Urscheler N et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80 (1): 54–8.
19. Bischoff HA, Conzelmann M, Lindemann D et al. Self-reported exercise before age 40: influence on quantitative skeletal ultrasound and fall risk in the elderly. Arch Phys Med Rehabil 2001; 82 (6): 801–6.

Л.И.Алексеева 

НИИ ревматологии РАМН, Москва